Gilda D’Incerti is the founder and CEO of technology solutions and compliance consulting services company PQE Group.
For more than 25 years, my work has revolved around one guiding principle: quality. In the life sciences sector, safeguarding data integrity, compliance and ethical practices has never been optional. It is the foundation of everything we do. AI is reshaping industries at an unprecedented speed, often sparking discussions that are driven by hype or fear about the future. Luckily, the pharmaceutical world offers a valuable blueprint on how to harness AI’s efficiency while protecting trust, ethics and above all, people.
How To Ensure AI Changes Work For The Better
AI is increasingly becoming part of our daily lives and professional workflows and organizations are exploring how algorithms can streamline operations, uncover insights and cut costs. A survey of 127 technology executives found that 95% believe AI and digital tools shape company strategy just as much, or even more, than traditional factors like shifting customer habits or rising costs.
In highly regulated sectors like pharmaceuticals, where a single error can affect patient safety, achieving the balance between innovation and precision is critical. The key is not simply adopting AI but embedding it with responsibility and oversight. While speed and cost do matter, quality, ethics and trust must come first because AI can only be transformative once it is genuinely trustworthy. Here’s how to achieve that:
Train employees to use AI as a tool, not a shortcut.
Research shared in the Harvard Business Review from BetterUp Labs highlights a growing workplace challenge: “workslop,” AI-generated work that appears competent but lacks the depth needed to advance a project meaningfully. Essentially, employees are using AI tools to produce low-effort, superficially acceptable work that can create extra tasks for colleagues. This illustrates how, without proper guidance and training, productivity gains can backfire. Leaders can address this by establishing clear standards for AI-assisted work, fostering a culture of accountability and ensuring that employees understand how to use AI as a tool to enhance, not shortcut, their contributions.
Recognize that data integrity is non-negotiable.
From early research to clinical trials to global distribution, every stage of pharmaceutical processes depends on information that is accurate, complete and consistent. This is what “data integrity” means in practice, and it reflects traceability, security and reliability at every step. Automated systems can process vast amounts of data at unprecedented speed, but if the inputs are biased, incomplete or poorly governed, the outputs will be equally flawed.
Without proper governance, AI and digital tools can magnify errors and erode trust. This is why keeping a “human in the loop” remains essential. Even as AI accelerates workflows, people provide the context, ethical reasoning and quality oversight that machines cannot replicate. Industries rushing to adopt AI must recognize that without robust data governance and ethical safeguards, insights can lose their value and turn from an asset into a liability.
Highlight the human role.
Some believe AI will replace human expertise. In the life sciences, the opposite is proving true. AI accelerates processes and scales tasks, but it cannot replace human oversight. Ethical decision-making, contextual judgment and accountability remain firmly human responsibilities. Rather than eliminating roles, AI is shifting them from “doing every step” to “ensuring quality, ethics, and fairness.”
AI can streamline audits, but human experts still need to decide when to escalate issues or adjust procedures. This evolving partnership between AI and people strengthens quality and creates resilience.
Remember that efficiency and ethics can coexist.
Institutions face growing pressure to do more with less, pushing for smarter, faster and more cost-effective ways to operate. In the United States, layoffs and restructuring have made efficiency a dominant theme, and AI is part of the answer. When implemented thoughtfully, it can reduce manual workloads, accelerate inspections and streamline documentation, all of which are areas where time equals money.
The pharmaceutical sector shows that efficiency and ethics are not opposing forces, and they can coexist when leadership prioritizes both from the start. NVIDIA’s State of AI in Healthcare and Life Sciences: 2025 Trends report (registration required) found that 63% of healthcare industry professionals are actively using AI, with 81% reporting increased revenue and 73% seeing reductions in operational costs. However, actual efficiency demands more than technology alone. It requires up-front investment in safeguards against bias. This reflects a broader, global debate over strong AI governance and emerging regulations. To help, the World Economic Forum launched its Industries in the Intelligent Age report series, providing actionable guidance for responsible AI adoption across key sectors.
In closing, AI without integrity is a liability; AI with integrity is a revolution. By using AI to reimagine how quality and compliance services are delivered, organizations can save time, reduce costs and uphold the highest ethical standards. But leaders across industries must approach these tools with humility, maintain human oversight and prioritize quality.
Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?